IARTHealthcare · Medical DevicesThe 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. hold a median 12-month price target of $19 — +13.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Integra LifeSciences Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Volatility (43): The share price moves around a lot.
Size (42): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IART, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +13.5% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Wells Fargo | Maintains | Equal-Weight | $15 → $18 |
| 28 July 2026 | UBS | Initiates | Neutral | $19 |
| 16 July 2026 | Truist Securities | Maintains | Hold | $14 → $19 |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | $19 |
| 9 July 2026 | BMO Capital | Initiates | Market Perform | — |
| 8 July 2026 | Citigroup | Maintains | Neutral | $16 → $19 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | Citigroup | Upgrade | Neutral | — |
| 6 May 2026 | Citigroup | Maintains | Sell | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 15 Apr 2026 | Argus Research | Downgrade | Hold | — |
| 15 Apr 2026 | Truist Securities | Maintains | Hold | — |
| 11 Mar 2026 | Citigroup | Maintains | Sell | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 3 Nov 2025 | Truist Securities | Reiterates | Hold | — |
| 31 Oct 2025 | Citigroup | Maintains | Sell | — |
| 31 Oct 2025 | JP Morgan | Maintains | Underweight | — |
| 15 Oct 2025 | Truist Securities | Maintains | Hold | — |
| 7 Oct 2025 | Citigroup | Maintains | Sell | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IART appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 11% of US stocks
Cheaper than 75% of US stocks
Cheaper than 66% of US stocks
Cheaper than 39% of US stocks
Higher than 29% of US stocks
Higher than 36% of US stocks
Higher than 66% of US stocks
Higher than 63% of US stocks
Higher than 30% of US stocks
Higher than 43% of US stocks
Higher than 64% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Integra LifeSciences Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
According to Zacks Investment Research, Integra's SurgiMend relaunch could support a broader 2027 recovery, though customer recapture and FDA approval remain key to the potential upside.
Why it matters — A IART watcher would care because SurgiMend's relaunch and regulatory progress are central to the company's anticipated recovery trajectory.
Zacks reports that Integra LifeSciences trades at a steep valuation discount while achieving margin gains and cost savings. However, modest growth, leverage and unresolved FDA risks keep execution concerns in focus.
Why it matters — A IART watcher would care because the combination of a low valuation with ongoing execution risks—including FDA uncertainty and leverage—shapes the company's near-term outlook.
Zacks Investment Research highlighted Integra LifeSciences (IART) as a strong momentum stock, using its Style Scores feature from the Zacks Premium research service to identify it among strong stocks.
Why it matters — IART watchers would care because Zacks' Style Scores flagged the company as a strong momentum stock, adding a research-based signal to their assessment of the company.
Seeking Alpha published the transcript of Integra LifeSciences' Q2 2026 earnings call, covering the company's financial results and management commentary for the period.
Why it matters — Investors following IART can review the full earnings call transcript for detailed management discussion on the company's quarterly performance and outlook.
Zacks Investment Research identified Integra LifeSciences (IART) as one of three stocks showing breakout potential, noting it is trading near its 52-week high after passing technical screens.
Why it matters — IART watchers would care because the article highlights the stock's recent technical momentum and suggests it could continue to perform well in the near term.
The 12 Wall Street analysts covering Integra LifeSciences Holdings Corp. have a median 12-month price target of $19, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Integra LifeSciences Holdings Corp., 3 rate it a Buy, 7 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Integra LifeSciences Holdings Corp. 89 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Integra LifeSciences Holdings Corp. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +13.5% from the last close, and Ticker Nerd's factor model ranks Integra LifeSciences Holdings Corp. 89 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Integra LifeSciences Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IART are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.
Integra LifeSciences Holdings Corp. returned +22.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Integra LifeSciences Holdings Corporation is a global medical technology company specializing in innovative solutions for neurosurgery, tissue reconstruction, and ear, nose, and throat procedures. The company operates through two primary business segments: Codman Specialty Surgical, which manufactures neurosurgical instruments and products including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, and intracranial monitoring equipment; and Tissue Technologies, which develops regenerative medicine products for wound care, soft tissue repair, and dermal reconstruction.
The most recent item we track (Zacks Investment Research, 20 Aug 2026): "Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?". According to Zacks Investment Research, Integra's SurgiMend relaunch could support a broader 2027 recovery, though customer recapture and FDA approval remain key to the potential upside.
Integra LifeSciences Holdings Corporation is a global medical technology company specializing in innovative solutions for neurosurgery, tissue reconstruction, and ear, nose, and throat procedures. The company operates through two primary business segments: Codman Specialty Surgical, which manufactures neurosurgical instruments and products including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, and intracranial monitoring equipment; and Tissue Technologies, which develops regenerative medicine products for wound care, soft tissue repair, and dermal reconstruction. Integra's portfolio includes highly differentiated surgical instruments, implants, and regenerative matrices developed through decades of clinical evidence. The company distributes its products globally across more than 120 countries through a combination of direct sales forces, distributors, and wholesalers, with significant presence in North America and international markets. Founded in 1989 and headquartered in Princeton, New Jersey, Integra serves healthcare professionals in neurosurgery, neurocritical care, and specialized surgical fields where precision and clinical outcomes are paramount.
CEO Dr. Stuart M. Essig Ph.D. · 4,427 employees · United States · https://www.integralife.com